Sentence: Five other treatments closely followed ( dabrafenib [ HR PFS : 0.30 ] , nivolumab plus ipilimumab [ HR PFS : 0.34 ] , vemurafenib [ HR PFS : 0.38 ] , nivolumab [ HR PFS : 0.42 ] and pembrolizumab [ HR PFS : 0.46 ] ) .
Drug combination annotation:
[{'class': 'POS', 'spans': ['nivolumab', 'ipilimumab'], 'is_context_needed': True}]